Department of Microbiology, Immunology, and Tropical Medicine and.
GW Cancer Center, The George Washington University, Washington, DC, USA.
J Clin Invest. 2022 Jul 15;132(14). doi: 10.1172/JCI160186.
Cancer cells resist the immune response in a process known as immune editing or immune evasion. Therapies that target the immune system have revolutionized cancer treatment; however, immunotherapies have been ineffective for the majority of ovarian cancer cases. In this issue of the JCI, Chen, Xie, et al. hypothesized that hypomethylating agent (HMA) treatment would induce antitumor immunity to sensitize patients with ovarian cancer to anti-PD-1 immunotherapy. The authors performed a phase II clinical trial to test the combination of guadecitabine, a second-generation HMA, along with pembrolizumab, an immune checkpoint inhibitor of PD-1. The trial included a group of 35 patients with platinum-resistant ovarian cancer. While the clinical benefit from the combined HMA plus immune checkpoint blockade regimen was lower than hoped, the correlate analyses gave important information about which patients with ovarian cancer may be more likely to respond to immune therapy.
癌细胞在免疫编辑或免疫逃逸过程中抵抗免疫反应。靶向免疫系统的疗法彻底改变了癌症治疗；然而，免疫疗法对大多数卵巢癌病例都无效。在本期 JCI 中，Chen、Xie 等人假设低甲基化剂（HMA）治疗会诱导抗肿瘤免疫，使卵巢癌患者对抗 PD-1 免疫疗法敏感。作者进行了一项 II 期临床试验，以测试第二代 HMA 加德西他滨与 PD-1 免疫检查点抑制剂 pembrolizumab 的联合用药。该试验包括 35 名铂类耐药卵巢癌患者。虽然联合 HMA 加免疫检查点阻断方案的临床获益低于预期，但相关分析提供了重要信息，说明哪些卵巢癌患者可能更有可能对免疫治疗产生反应。
